Titlebook: Coronary Artery Disease: Therapeutics and Drug Discovery; Miao Wang Book 2020 Springer Nature Singapore Pte Ltd. 2020 coronary artery dise

DUCE

nocturnal

民間傳說

Revascularization for Coronary Artery Disease: Principle and Challenges,rtant determinants of patient outcomes. Multidisciplinary decision-making should analyze current evidence, considering the clinical condition of patients, and determine the safety and necessity for coronary revascularization with either PCI or CABG. For coronary artery disease with more complex lesi

Ostrich

Drug Discovery for Coronary Artery Disease,ing atherothrombosis opens a new era of therapeutic discovery that targets inflammation. Chinese traditional medicine and cardiac regeneration are also discussed. Human genetics studies of CAD and further delineation of key determinants/pathways underlying the residual risk of CAD under current stan

PLAYS

delusion

Welcome Address by the Conference Chairmant patients. While cumulating studies have focused on optimizing pharmacological therapy (referring to nitrates, beta-blockers, calcium channel blockers, antiplatelet agents, ACEI/ARB, statins, etc.), education, habitual modification, and social support matters a lot for reducing cardiac morbidity an

蘑菇

G. F. Bennett,E. C. Greiner,W. Threlfallrtant determinants of patient outcomes. Multidisciplinary decision-making should analyze current evidence, considering the clinical condition of patients, and determine the safety and necessity for coronary revascularization with either PCI or CABG. For coronary artery disease with more complex lesi

spondylosis

使苦惱

0065-2598 owing chapters provide an overview of three major categories of coronary artery disease drugs, which target thrombosis (Chapter 4), lipid metabolism (Chapter 5), and hypertension (Chapter 6). Heart failure cons978-981-15-2519-3978-981-15-2517-9Series ISSN 0065-2598 Series E-ISSN 2214-8019

delegate